TTGM 5826

TTGM 5826 (30 μM; 6 days) potently inhibits the growth of onco-Dbl-transformed MEF cells, while exerting minimal effects on untransformed MEF cells^[1].
TTGM 5826 (6 days) inhibits the growth of tTG-expressing cancer cell lines and GSCs, with IC₅₀ values ranging from 11 μM (GSC267) to 30 μM (Mia-PaCa-2, U-87 MG); it shows no effect on tTG-negative T47D and HME-1 cells, and exhibits enhanced activity against T98G cells with retinoic acid (HY-14649)-induced tTG upregulation^[1].
TTGM 5826 (15 μM; 12-36 h) significantly inhibits the migration of MDA-MB-231, U-87 MG and LN229 cancer cells^[1].
TTGM 5826 (15-30 μM; 10 days) completely blocks colony formation of MDA-MB-231 cells and potently inhibits colony formation of LN229 cells^[1].
TTGM 5826 (30-120 μM; 14 days) inhibits the anchorage-independent growth of LN229 and U-87 MG glioblastoma cells in a dose-dependent manner, with an inhibition rate of approximately 80%-85% at concentrations of 60-120 μM^[1].
TTGM 5826 (6.3-50.0 μM; 3 days) inhibits sphere formation (a marker of stem cell properties) in GSC374 and GSC267 glioma stem cells in a dose-dependent manner, and almost completely abolishes sphere formation at 50 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.